On The Behalf of The GALILEO Investigators - ppt download
A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement | NEJM
Galileo Research Fact Sheet #138: Can Galileo Therapy decrease the development of Scoliosis? - Novotec Medical und Stratec Medizintechnik GmbH
Rivaroxaban-based antithrombotic strategy vs antiplatelet-based strategy after TAVR to optimize clinical outcomes: GALILEO
The GALILEO Trial: Inova Researchers Study New Drug Therapy for Heart Patients - Inova Newsroom
Goal-directed fluid therapy vs. low central venous pressure during major open liver resections (GALILEO): a surgeon- and patient-blinded randomized controlled trial - HPB
ESC 365 - Doctor Georg Marcus Froehlich
A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement | NEJM
Predicting the Future: Will the Ongoing GALILEO and ENVISAGE AF Trials Change How We Anticoagulate Patients After TAVR? | tctmd.com
The ATLANTIS Randomized Trial: Apixaban Versus Standard of Care After TAVI - Cardiac Interventions Today
Full GALILEO Results Confirm Harm With Rivaroxaban After TAVR | tctmd.com
The ATLANTIS Randomized Trial: Apixaban Versus Standard of Care After TAVI - Cardiac Interventions Today
Optimal Antithrombotic Strategy After Transcatheter Aortic Valve Replacement: Is the “Less Is More” Concept Always Better? | Journal of the American Heart Association
GALILEO 4D - STUDY DESIGN
OAC in TAVR: Failed Galileo
Routine anticoagulation with rivaroxaban after TAVI harmful: GALILEO
Rationale and design of the ADAPT-TAVR trial: a randomised comparison of edoxaban and dual antiplatelet therapy for prevention of leaflet thrombosis and cerebral embolisation after transcatheter aortic valve replacement | BMJ Open
Clinical Trial Results in MEfRVO | EYLEA® (aflibercept) Injection
PDF) Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study
Antithrombotic Therapy After Transcatheter Aortic Valve Replacement | Circulation: Cardiovascular Interventions
A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement | NEJM
GALILEO
GALILEO Trial
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study - ScienceDirect
Anticoagulation Therapy in Patients Post-TAVR - ppt download
